Dexketoprofen

CHEMBL75435 Phase 4 已批准 Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
254.3 g/mol
LogP
3.1
Phase
4

The pharmacologically active S-enantiomer of the NSAID ketoprofen, used for short-term treatment of mild-to-moderate pain including musculoskeletal conditions, dysmenorrhea, and dental pain. Isolating the active enantiomer may provide an improved side-effect profile at lower doses.

分子量

254.2800 g/mol

LogP

3.10

TPSA

54.40 Ų

Lipinski 五规则

符合

治疗领域

作用机制

Inhibits cyclooxygenase (COX-1 and/or COX-2) enzymes, reducing the synthesis of prostaglandins and thromboxanes from arachidonic acid. This produces anti-inflammatory, analgesic, and antipyretic effects.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

机制

Inhibits cyclooxygenase (COX-1 and/or COX-2) enzymes, reducing the synthesis of prostaglandins and thromboxanes from arachidonic acid. This produces anti-inflammatory, analgesic, and antipyretic effects.

二维结构

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

C[C@H](C(=O)O)c1cccc(C(=O)c2ccccc2)c1

InChI

InChI=1S/C16H14O3/c1-11(16(18)19)13-8-5-9-14(10-13)15(17)12-6-3-2-4-7-12/h2-11H,1H3,(H,18,19)/t11-/m0/s1

Molecular Formula

C16H14O3

HBD / HBA

1 / 3

可旋转键数

4

重原子数

19

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

常见问题

The pharmacologically active S-enantiomer of the NSAID ketoprofen, used for short-term treatment of mild-to-moderate pain including musculoskeletal conditions, dysmenorrhea, and dental pain. Isolating the active enantiomer may provide an improved side-effect profile at lower doses.

Inhibits cyclooxygenase (COX-1 and/or COX-2) enzymes, reducing the synthesis of prostaglandins and thromboxanes from arachidonic acid. This produces anti-inflammatory, analgesic, and antipyretic effects.

Yes, Dexketoprofen is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL75435. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 667550. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

医疗免责声明

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.